Full Generic Medicine Info
Dosage/Direction for Use

Adult: As sulfate: 12.5 mg bid. Max: 50 mg bid.
Max Dosage: 50 mg bid.
Renal impairment: Dosage adjustments may be needed.
Hepatic impairment: Dosage adjustments may be needed.
Severe tachycardia, dissecting aortic aneurysm, heart failure with high cardiac output, cor pulmonale, MI due to mechanical obstruction, idiopathic SLE and related disorders. Porphyria. 1st 2 trimesters during pregnancy.
Special Precautions
Ischaemic heart disaease, MI, cerebrovascular disorders, renal or hepatic impairment. Monitor for postural hypotension and tachycardia during initial therapy if given to patients with heart failure. Gradual withdrawal is advisable.
Adverse Reactions
Tachycardia, palpitations, angina pectoris, severe headache, GI disturbances, flushing, dizziness, nasal congestion, postural hypotension, fluid retention with oedema and wt gain, conjunctivitis, lachrymation, tremor, peripheral neuropathy with numbness and tingling of extremities, muscle cramps, hepatotoxicity, blood dyscrasias, haemolytic anaemia, difficulty in urinating, glomerulonephritis, constipation, paralytic ileus, depression, anxiety, hypersensitivity reactions, eosinophilia. A condition resembling SLE with prolonged use of large doses.
Drug Interactions
Agents with hypotensive action, diazoxide, thiazide diuretics.
Dihydralazine is a direct-acting vasodilator which acts predominantly on the arterioles. It reduces BP and peripheral resistance thus increasing cardiac output. It also tends to improve renal and cerebral blood flow and its effect on diastolic pressure is more marked than on systolic pressure.
CIMS Class
Other Antihypertensives
ATC Classification
C02DB01 - dihydralazine ; Belongs to the class of hydrazinophthalazine derivatives. Used in the treatment of hypertension.
Disclaimer: This information is independently developed by CIMS based on dihydralazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in